All the news Showing 10 of 39 articles from: Treatment for previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections Keith Alcorn / 11 April 2014 A 12-week course of three direct-acting antivirals developed by AbbVie, plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C genotype 1 infection, Professor Stefan Zeuzem of the JW Goethe University Hospital, Frankfurt, ... US medical societies launch new hepatitis C treatment guidelines Liz Highleyman / 30 January 2014 The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first new hepatitis C treatment guidelines ... Daclatasvir + sofosbuvir shows high hep C cure rate, new studies underway Liz Highleyman / 22 January 2014 A dual oral regimen of daclatasvir plus sofosbuvir cured more than 90% of chronic hepatitis C patients without interferon or ribavirin, according to a report in the January 16, 2014, New England Journal of ... Faldaprevir safe and effective in HCV treatment-experienced patients Michael Carter / 13 December 2013 Triple therapy including the investigational hepatitis C virus (HCV) protease inhibitor faldaprevir is a safe and effective treatment for people who did not respond to a previous course of HCV treatment, results of ... Simeprevir + sofosbuvir produces high sustained response rates for hard-to-treat patients in COSMOS trial Liz Highleyman / 06 November 2013 A 12-week all-oral combination of simeprevir plus sofosbuvir led to sustained virological response (SVR12) in 93% of genotype 1 prior null responders with mild-to-moderate liver fibrosis, working as well as a longer course ... Two new hepatitis C drugs recommended for US approval Keith Alcorn / 02 November 2013 Two new direct acting antiviral agents for the treatment of hepatitis C have been unanimously recommended for approval by expert advisory panels in the United States. Full marketing approval from the US ... Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection Liz Highleyman / 22 October 2013 The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks after completing treatment, according to a ... Interferon-free simeprevir + sofosbuvir suppresses hepatitis C with or without ribavirin Liz Highleyman / 17 June 2013 An all-oral regimen consisting of simeprevir (formerly TMC435) plus sofosbuvir, (formerly GS-7977), with or without ribavirin, produced an 8-week post-treatment sustained response for most prior null responders with genotype 1 hepatitis C in ... Simeprevir boosts response to interferon-based hepatitis C therapy for prior relapsers Liz Highleyman / 03 June 2013 Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after three months, according to ... Vaniprevir boosts interferon/ribavirin response rate for prior non-responders with cirrhosis Liz Highleyman / 13 May 2013 The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive